Oncoheroes Biosciences was founded by two fathers whose personal experiences with childhood cancer ignited a passionate vision for change. Recognizing the urgent need for dedicated advancement in pediatric oncology therapies, they embarked on a mission to make a difference.
Since its inception in 2017, Oncoheroes Biosciences has rapidly evolved, buoyed by the unwavering support of numerous foundations worldwide. With their backing, we've built a portfolio featuring three clinic-ready compounds, poised to address eight different types of pediatric cancer indications. Now, our primary goal is securing the necessary funding to propel the testing of our lead compound, volasertib, in five types of pediatric cancer (Ewing’s sarcoma, alveolar rhabdomyosarcoma, medulloblastoma, neuroblastoma and DMG including DIPG).
In collaboration with Hopp Children’s Cancer Center Heidelberg (KiTZ), this trial will span 20 sites across multiple countries, enrolling approximately 110 patients who have exhausted their treatment options.
We extend our deepest gratitude to all the non-profits, organizations, and individuals committed to our mission. Your steadfast support has been instrumental in our journey thus far, and we look forward to continuing this vital work together in the chapters ahead.